Background:
- An immunosuppressive TIME can reduce the efficacy of immune checkpoint inhibitors (ICI) in GI cancers.
- GUCY2C is preferentially expressed in colorectal (CRC), gastroesophageal junction (EJC) and gastric adenocarcinoma (GA).
- There is currently an ongoing trial of GUCY2C-directed bispecific T cell engager in advanced GI cancers.
- Better characterization of the TIME of GUCY2C-high GI cancers will be important as additional directed immunotherapies are developed.